CN104854103A - 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 - Google Patents
适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 Download PDFInfo
- Publication number
- CN104854103A CN104854103A CN201380067566.XA CN201380067566A CN104854103A CN 104854103 A CN104854103 A CN 104854103A CN 201380067566 A CN201380067566 A CN 201380067566A CN 104854103 A CN104854103 A CN 104854103A
- Authority
- CN
- China
- Prior art keywords
- ethyl
- pyrimidine
- tertiary butyl
- cyclohexyl
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C1*)N(**=CC(C2)CC2NC(*)=O)C*N1c1nc(C(C)(C)C)nc(*)c1 Chemical compound CC(C1*)N(**=CC(C2)CC2NC(*)=O)C*N1c1nc(C(C)(C)C)nc(*)c1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Description
# | R1 | R3a | R3b | R5 |
1. | CH3 | H | H | 甲氧基甲基 |
2. | CH3 | H | H | 2-甲氧基乙基 |
3. | CH3 | H | H | 乙氧基甲基 |
4. | CH3 | H | H | 二氟甲氧基甲基 |
5. | CH3 | H | H | 2-(二氟甲氧基)乙基 |
6. | CH3 | H | H | 三氟甲氧基甲基 |
7. | CH3 | H | H | 2-(三氟甲氧基)乙基 |
8. | CH3 | H | H | 甲氧基二氟甲基 |
9. | CH3 | H | H | 乙氧基二氟甲基 |
10. | CH3 | H | H | 2-甲氧基-1,1-二氟乙基 |
11. | CH3 | H | H | 羟基甲基 |
12. | CH3 | H | H | 2-羟基乙基 |
13. | CH3 | H | H | 2-羟基丙基 |
14. | CH3 | H | H | 2-羟基-2-甲基丙基 |
15. | CH3 | H | H | 氧杂环丁烷-2-基 |
16. | CH3 | H | H | 氧杂环丁烷-3-基 |
17. | CH3 | H | H | 氧杂环戊烷-2-基 |
18. | CH3 | H | H | 氧杂环戊烷-3-基 |
19. | CH3 | H | H | 3-甲氧基环丁基 |
20. | CH3 | H | H | 3-羟基环丁基 |
21. | H | H | H | 甲氧基甲基 |
22. | H | H | H | 2-甲氧基乙基 |
23. | H | H | H | 乙氧基甲基 |
24. | H | H | H | 二氟甲氧基甲基 |
25. | H | H | H | 2-(二氟甲氧基)乙基 |
26. | H | H | H | 三氟甲氧基甲基 |
27. | H | H | H | 2-(三氟甲氧基)乙基 |
28. | H | H | H | 甲氧基二氟甲基 |
29. | H | H | H | 乙氧基二氟甲基 |
30. | H | H | H | 2-甲氧基-1,1-二氟乙基 |
31. | H | H | H | 羟基甲基 |
32. | H | H | H | 2-羟基乙基 |
33. | H | H | H | 2-羟基丙基 |
34. | H | H | H | 2-羟基-2-甲基丙基 |
35. | H | H | H | 氧杂环丁烷-2-基 |
36. | H | H | H | 氧杂环丁烷-3-基 |
37. | H | H | H | 氧杂环戊烷-2-基 |
38. | H | H | H | 氧杂环戊烷-3-基 |
39. | H | H | H | 3-甲氧基环丁基 |
40. | H | H | H | 3-羟基环丁基 |
41. | CH3 | H | (外消旋) CH3 | 甲氧基甲基 |
42. | CH3 | H | (外消旋) CH3 | 2-甲氧基乙基 |
43. | CH3 | H | (外消旋) CH3 | 乙氧基甲基 |
44. | CH3 | H | (外消旋) CH3 | 二氟甲氧基甲基 |
45. | CH3 | H | (外消旋) CH3 | 2-(二氟甲氧基)乙基 |
46. | CH3 | H | (外消旋) CH3 | 三氟甲氧基甲基 |
47. | CH3 | H | (外消旋) CH3 | 2-(三氟甲氧基)乙基 |
48. | CH3 | H | (外消旋) CH3 | 甲氧基二氟甲基 |
49. | CH3 | H | (外消旋) CH3 | 乙氧基二氟甲基 |
50. | CH3 | H | (外消旋) CH3 | 2-甲氧基-1,1-二氟乙基 |
51. | CH3 | H | (外消旋) CH3 | 羟基甲基 |
52. | CH3 | H | (外消旋) CH3 | 2-羟基乙基 |
53. | CH3 | H | (外消旋) CH3 | 2-羟基丙基 |
54. | CH3 | H | (外消旋) CH3 | 2-羟基-2-甲基丙基 |
55. | CH3 | H | (外消旋) CH3 | 氧杂环丁烷-2-基 |
56. | CH3 | H | (外消旋) CH3 | 氧杂环丁烷-3-基 |
57. | CH3 | H | (外消旋) CH3 | 氧杂环戊烷-2-基 |
58. | CH3 | H | (外消旋) CH3 | 氧杂环戊烷-3-基 |
59. | CH3 | H | (外消旋) CH3 | 3-甲氧基环丁基 |
60. | CH3 | H | (外消旋) CH3 | 3-羟基环丁基 |
61. | H | H | (外消旋) CH3 | 甲氧基甲基 |
62. | H | H | (外消旋) CH3 | 2-甲氧基乙基 |
63. | H | H | (外消旋) CH3 | 乙氧基甲基 |
64. | H | H | (外消旋) CH3 | 二氟甲氧基甲基 |
65. | H | H | (外消旋) CH3 | 2-(二氟甲氧基)乙基 |
66. | H | H | (外消旋) CH3 | 三氟甲氧基甲基 |
67. | H | H | (外消旋) CH3 | 2-(三氟甲氧基)乙基 |
68. | H | H | (外消旋) CH3 | 甲氧基二氟甲基 |
69. | H | H | (外消旋) CH3 | 乙氧基二氟甲基 |
70. | H | H | (外消旋) CH3 | 2-甲氧基-1,1-二氟乙基 |
71. | H | H | (外消旋) CH3 | 羟基甲基 |
72. | H | H | (外消旋) CH3 | 2-羟基乙基 |
73. | H | H | (外消旋) CH3 | 2-羟基丙基 |
74. | H | H | (外消旋) CH3 | 2-羟基-2-甲基丙基 |
75. | H | H | (外消旋) CH3 | 氧杂环丁烷-2-基 |
76. | H | H | (外消旋) CH3 | 氧杂环丁烷-3-基 |
77. | H | H | (外消旋) CH3 | 氧杂环戊烷-2-基 |
78. | H | H | (外消旋) CH3 | 氧杂环戊烷-3-基 |
79. | H | H | (外消旋) CH3 | 3-甲氧基环丁基 |
80. | H | H | (外消旋) CH3 | 3-羟基环丁基 |
81. | CH3 | H | (S) CH3 | 甲氧基甲基 |
82. | CH3 | H | (S) CH3 | 2-甲氧基乙基 |
83. | CH3 | H | (S) CH3 | 乙氧基甲基 |
84. | CH3 | H | (S) CH3 | 二氟甲氧基甲基 |
85. | CH3 | H | (S) CH3 | 2-(二氟甲氧基)乙基 |
86. | CH3 | H | (S) CH3 | 三氟甲氧基甲基 |
87. | CH3 | H | (S) CH3 | 2-(三氟甲氧基)乙基 |
88. | CH3 | H | (S) CH3 | 甲氧基二氟甲基 |
89. | CH3 | H | (S) CH3 | 乙氧基二氟甲基 |
90. | CH3 | H | (S) CH3 | 2-甲氧基-1,1-二氟乙基 |
91. | CH3 | H | (S) CH3 | 羟基甲基 |
92. | CH3 | H | (S) CH3 | 2-羟基乙基 |
93. | CH3 | H | (S) CH3 | 2-羟基丙基 |
94. | CH3 | H | (S) CH3 | 2-羟基-2-甲基丙基 |
95. | CH3 | H | (S) CH3 | 氧杂环丁烷-2-基 |
96. | CH3 | H | (S) CH3 | 氧杂环丁烷-3-基 |
97. | CH3 | H | (S) CH3 | 氧杂环戊烷-2-基 |
98. | CH3 | H | (S) CH3 | 氧杂环戊烷-3-基 |
99. | CH3 | H | (S) CH3 | 3-甲氧基环丁基 |
100. | CH3 | H | (S) CH3 | 3-羟基环丁基 |
101. | H | H | (S) CH3 | 甲氧基甲基 |
102. | H | H | (S) CH3 | 2-甲氧基乙基 |
103. | H | H | (S) CH3 | 乙氧基甲基 |
104. | H | H | (S) CH3 | 二氟甲氧基甲基 |
105. | H | H | (S) CH3 | 2-(二氟甲氧基)乙基 |
106. | H | H | (S) CH3 | 三氟甲氧基甲基 |
107. | H | H | (S) CH3 | 2-(三氟甲氧基)乙基 |
108. | H | H | (S) CH3 | 甲氧基二氟甲基 |
109. | H | H | (S) CH3 | 乙氧基二氟甲基 |
110. | H | H | (S) CH3 | 2-甲氧基-1,1-二氟乙基 |
111. | H | H | (S) CH3 | 羟基甲基 |
112. | H | H | (S) CH3 | 2-羟基乙基 |
113. | H | H | (S) CH3 | 2-羟基丙基 |
114. | H | H | (S) CH3 | 2-羟基-2-甲基丙基 |
115. | H | H | (S) CH3 | 氧杂环丁烷-2-基 |
116. | H | H | (S) CH3 | 氧杂环丁烷-3-基 |
117. | H | H | (S) CH3 | 氧杂环戊烷-2-基 |
118. | H | H | (S) CH3 | 氧杂环戊烷-3-基 |
119. | H | H | (S) CH3 | 3-甲氧基环丁基 |
120. | H | H | (S) CH3 | 3-羟基环丁基 |
121. | CH3 | H | (R) CH3 | 甲氧基甲基 |
122. | CH3 | H | (R) CH3 | 2-甲氧基乙基 |
123. | CH3 | H | (R) CH3 | 乙氧基甲基 |
124. | CH3 | H | (R) CH3 | 二氟甲氧基甲基 |
125. | CH3 | H | (R) CH3 | 2-(二氟甲氧基)乙基 |
126. | CH3 | H | (R) CH3 | 三氟甲氧基甲基 |
127. | CH3 | H | (R) CH3 | 2-(三氟甲氧基)乙基 |
128. | CH3 | H | (R) CH3 | 甲氧基二氟甲基 |
129. | CH3 | H | (R) CH3 | 乙氧基二氟甲基 |
130. | CH3 | H | (R) CH3 | 2-甲氧基-1,1-二氟乙基 |
131. | CH3 | H | (R) CH3 | 羟基甲基 |
132. | CH3 | H | (R) CH3 | 2-羟基乙基 |
133. | CH3 | H | (R) CH3 | 2-羟基丙基 |
134. | CH3 | H | (R) CH3 | 2-羟基-2-甲基丙基 |
135. | CH3 | H | (R) CH3 | 氧杂环丁烷-2-基 |
136. | CH3 | H | (R) CH3 | 氧杂环丁烷-3-基 |
137. | CH3 | H | (R) CH3 | 氧杂环戊烷-2-基 |
138. | CH3 | H | (R) CH3 | 氧杂环戊烷-3-基 |
139. | CH3 | H | (R) CH3 | 3-甲氧基环丁基 |
140. | CH3 | H | (R) CH3 | 3-羟基环丁基 |
141. | H | H | (R) CH3 | 甲氧基甲基 |
142. | H | H | (R) CH3 | 2-甲氧基乙基 |
143. | H | H | (R) CH3 | 乙氧基甲基 |
144. | H | H | (R) CH3 | 二氟甲氧基甲基 |
145. | H | H | (R) CH3 | 2-(二氟甲氧基)乙基 |
146. | H | H | (R) CH3 | 三氟甲氧基甲基 |
147. | H | H | (R) CH3 | 2-(三氟甲氧基)乙基 |
148. | H | H | (R) CH3 | 甲氧基二氟甲基 |
149. | H | H | (R) CH3 | 乙氧基二氟甲基 |
150. | H | H | (R) CH3 | 2-甲氧基-1,1-二氟乙基 |
151. | H | H | (R) CH3 | 羟基甲基 |
152. | H | H | (R) CH3 | 2-羟基乙基 |
153. | H | H | (R) CH3 | 2-羟基丙基 |
154. | H | H | (R) CH3 | 2-羟基-2-甲基丙基 |
155. | H | H | (R) CH3 | 氧杂环丁烷-2-基 |
156. | H | H | (R) CH3 | 氧杂环丁烷-3-基 |
157. | H | H | (R) CH3 | 氧杂环戊烷-2-基 |
158. | H | H | (R) CH3 | 氧杂环戊烷-3-基 |
159. | H | H | (R) CH3 | 3-甲氧基环丁基 |
160. | H | H | (R) CH3 | 3-羟基环丁基 |
161. | CH3 | (外消旋) CH3 | H | 甲氧基甲基 |
162. | CH3 | (外消旋) CH3 | H | 2-甲氧基乙基 |
163. | CH3 | (外消旋) CH3 | H | 乙氧基甲基 |
164. | CH3 | (外消旋) CH3 | H | 二氟甲氧基甲基 |
165. | CH3 | (外消旋) CH3 | H | 2-(二氟甲氧基)乙基 |
166. | CH3 | (外消旋) CH3 | H | 三氟甲氧基甲基 |
167. | CH3 | (外消旋) CH3 | H | 2-(三氟甲氧基)乙基 |
168. | CH3 | (外消旋) CH3 | H | 甲氧基二氟甲基 |
169. | CH3 | (外消旋) CH3 | H | 乙氧基二氟甲基 |
170. | CH3 | (外消旋) CH3 | H | 2-甲氧基-1,1-二氟乙基 |
171. | CH3 | (外消旋) CH3 | H | 羟基甲基 |
172. | CH3 | (外消旋) CH3 | H | 2-羟基乙基 |
173. | CH3 | (外消旋) CH3 | H | 2-羟基丙基 |
174. | CH3 | (外消旋) CH3 | H | 2-羟基-2-甲基丙基 |
175. | CH3 | (外消旋) CH3 | H | 氧杂环丁烷-2-基 |
176. | CH3 | (外消旋) CH3 | H | 氧杂环丁烷-3-基 |
177. | CH3 | (外消旋) CH3 | H | 氧杂环戊烷-2-基 |
178. | CH3 | (外消旋) CH3 | H | 氧杂环戊烷-3-基 |
179. | CH3 | (外消旋) CH3 | H | 3-甲氧基环丁基 |
180. | CH3 | (外消旋) CH3 | H | 3-羟基环丁基 |
181. | H | (外消旋) CH3 | H | 甲氧基甲基 |
182. | H | (外消旋) CH3 | H | 2-甲氧基乙基 |
183. | H | (外消旋) CH3 | H | 乙氧基甲基 |
184. | H | (外消旋) CH3 | H | 二氟甲氧基甲基 |
185. | H | (外消旋) CH3 | H | 2-(二氟甲氧基)乙基 |
186. | H | (外消旋) CH3 | H | 三氟甲氧基甲基 |
187. | H | (外消旋) CH3 | H | 2-(三氟甲氧基)乙基 |
188. | H | (外消旋) CH3 | H | 甲氧基二氟甲基 |
189. | H | (外消旋) CH3 | H | 乙氧基二氟甲基 |
190. | H | (外消旋) CH3 | H | 2-甲氧基-1,1-二氟乙基 |
191. | H | (外消旋) CH3 | H | 羟基甲基 |
192. | H | (外消旋) CH3 | H | 2-羟基乙基 |
193. | H | (外消旋) CH3 | H | 2-羟基丙基 |
194. | H | (外消旋) CH3 | H | 2-羟基-2-甲基丙基 |
195. | H | (外消旋) CH3 | H | 氧杂环丁烷-2-基 |
196. | H | (外消旋) CH3 | H | 氧杂环丁烷-3-基 |
197. | H | (外消旋) CH3 | H | 氧杂环戊烷-2-基 |
198. | H | (外消旋) CH3 | H | 氧杂环戊烷-3-基 |
199. | H | (外消旋) CH3 | H | 3-甲氧基环丁基 |
200. | H | (外消旋) CH3 | H | 3-羟基环丁基 |
201. | CH3 | (S) CH3 | H | 甲氧基甲基 |
202. | CH3 | (S) CH3 | H | 2-甲氧基乙基 |
203. | CH3 | (S) CH3 | H | 乙氧基甲基 |
204. | CH3 | (S) CH3 | H | 二氟甲氧基甲基 |
205. | CH3 | (S) CH3 | H | 2-(二氟甲氧基)乙基 |
206. | CH3 | (S) CH3 | H | 三氟甲氧基甲基 |
207. | CH3 | (S) CH3 | H | 2-(三氟甲氧基)乙基 |
208. | CH3 | (S) CH3 | H | 甲氧基二氟甲基 |
209. | CH3 | (S) CH3 | H | 乙氧基二氟甲基 |
210. | CH3 | (S) CH3 | H | 2-甲氧基-1,1-二氟乙基 |
211. | CH3 | (S) CH3 | H | 羟基甲基 |
212. | CH3 | (S) CH3 | H | 2-羟基乙基 |
213. | CH3 | (S) CH3 | H | 2-羟基丙基 |
214. | CH3 | (S) CH3 | H | 2-羟基-2-甲基丙基 |
215. | CH3 | (S) CH3 | H | 氧杂环丁烷-2-基 |
216. | CH3 | (S) CH3 | H | 氧杂环丁烷-3-基 |
217. | CH3 | (S) CH3 | H | 氧杂环戊烷-2-基 |
218. | CH3 | (S) CH3 | H | 氧杂环戊烷-3-基 |
219. | CH3 | (S) CH3 | H | 3-甲氧基环丁基 |
220. | CH3 | (S) CH3 | H | 3-羟基环丁基 |
221. | H | (S) CH3 | H | 甲氧基甲基 |
222. | H | (S) CH3 | H | 2-甲氧基乙基 |
223. | H | (S) CH3 | H | 乙氧基甲基 |
224. | H | (S) CH3 | H | 二氟甲氧基甲基 |
225. | H | (S) CH3 | H | 2-(二氟甲氧基)乙基 |
226. | H | (S) CH3 | H | 三氟甲氧基甲基 |
227. | H | (S) CH3 | H | 2-(三氟甲氧基)乙基 |
228. | H | (S) CH3 | H | 甲氧基二氟甲基 |
229. | H | (S) CH3 | H | 乙氧基二氟甲基 |
230. | H | (S) CH3 | H | 2-甲氧基-1,1-二氟乙基 |
231. | H | (S) CH3 | H | 羟基甲基 |
232. | H | (S) CH3 | H | 2-羟基乙基 |
233. | H | (S) CH3 | H | 2-羟基丙基 |
234. | H | (S) CH3 | H | 2-羟基-2-甲基丙基 |
235. | H | (S) CH3 | H | 氧杂环丁烷-2-基 |
236. | H | (S) CH3 | H | 氧杂环丁烷-3-基 |
237. | H | (S) CH3 | H | 氧杂环戊烷-2-基 |
238. | H | (S) CH3 | H | 氧杂环戊烷-3-基 |
239. | H | (S) CH3 | H | 3-甲氧基环丁基 |
240. | H | (S) CH3 | H | 3-羟基环丁基 |
241. | CH3 | (R) CH3 | H | 甲氧基甲基 |
242. | CH3 | (R) CH3 | H | 2-甲氧基乙基 |
243. | CH3 | (R) CH3 | H | 乙氧基甲基 |
244. | CH3 | (R) CH3 | H | 二氟甲氧基甲基 |
245. | CH3 | (R) CH3 | H | 2-(二氟甲氧基)乙基 |
246. | CH3 | (R) CH3 | H | 三氟甲氧基甲基 |
247. | CH3 | (R) CH3 | H | 2-(三氟甲氧基)乙基 |
248. | CH3 | (R) CH3 | H | 甲氧基二氟甲基 |
249. | CH3 | (R) CH3 | H | 乙氧基二氟甲基 |
250. | CH3 | (R) CH3 | H | 2-甲氧基-1,1-二氟乙基 |
251. | CH3 | (R) CH3 | H | 羟基甲基 |
252. | CH3 | (R) CH3 | H | 2-羟基乙基 |
253. | CH3 | (R) CH3 | H | 2-羟基丙基 |
254. | CH3 | (R) CH3 | H | 2-羟基-2-甲基丙基 |
255. | CH3 | (R) CH3 | H | 氧杂环丁烷-2-基 |
256. | CH3 | (R) CH3 | H | 氧杂环丁烷-3-基 |
257. | CH3 | (R) CH3 | H | 氧杂环戊烷-2-基 |
258. | CH3 | (R) CH3 | H | 氧杂环戊烷-3-基 |
259. | CH3 | (R) CH3 | H | 3-甲氧基环丁基 |
260. | CH3 | (R) CH3 | H | 3-羟基环丁基 |
261. | H | (R) CH3 | H | 甲氧基甲基 |
262. | H | (R) CH3 | H | 2-甲氧基乙基 |
263. | H | (R) CH3 | H | 乙氧基甲基 |
264. | H | (R) CH3 | H | 二氟甲氧基甲基 |
265. | H | (R) CH3 | H | 2-(二氟甲氧基)乙基 |
266. | H | (R) CH3 | H | 三氟甲氧基甲基 |
267. | H | (R) CH3 | H | 2-(三氟甲氧基)乙基 |
268. | H | (R) CH3 | H | 甲氧基二氟甲基 |
269. | H | (R) CH3 | H | 乙氧基二氟甲基 |
270. | H | (R) CH3 | H | 2-甲氧基-1,1-二氟乙基 |
271. | H | (R) CH3 | H | 羟基甲基 |
272. | H | (R) CH3 | H | 2-羟基乙基 |
273. | H | (R) CH3 | H | 2-羟基丙基 |
274. | H | (R) CH3 | H | 2-羟基-2-甲基丙基 |
275. | H | (R) CH3 | H | 氧杂环丁烷-2-基 |
276. | H | (R) CH3 | H | 氧杂环丁烷-3-基 |
277. | H | (R) CH3 | H | 氧杂环戊烷-2-基 |
278. | H | (R) CH3 | H | 氧杂环戊烷-3-基 |
279. | H | (R) CH3 | H | 3-甲氧基环丁基 |
280. | H | (R) CH3 | H | 3-羟基环丁基 |
Claims (33)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261716824P | 2012-10-22 | 2012-10-22 | |
US61/716824 | 2012-10-22 | ||
US201361777114P | 2013-03-12 | 2013-03-12 | |
US61/777114 | 2013-03-12 | ||
PCT/EP2013/071947 WO2014064038A1 (en) | 2012-10-22 | 2013-10-21 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104854103A true CN104854103A (zh) | 2015-08-19 |
CN104854103B CN104854103B (zh) | 2018-01-02 |
Family
ID=49515329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380067566.XA Expired - Fee Related CN104854103B (zh) | 2012-10-22 | 2013-10-21 | 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 |
Country Status (18)
Country | Link |
---|---|
US (1) | US9376396B2 (zh) |
EP (1) | EP2909201B1 (zh) |
JP (1) | JP2016500683A (zh) |
KR (1) | KR20150074154A (zh) |
CN (1) | CN104854103B (zh) |
AR (1) | AR093099A1 (zh) |
AU (1) | AU2013336787B2 (zh) |
BR (1) | BR112015008992A2 (zh) |
CA (1) | CA2890247A1 (zh) |
IL (1) | IL238392A (zh) |
IN (1) | IN2015DN03837A (zh) |
MX (1) | MX2015005093A (zh) |
NZ (1) | NZ630281A (zh) |
RU (1) | RU2015119241A (zh) |
SG (1) | SG11201503144VA (zh) |
TW (1) | TWI607003B (zh) |
UY (1) | UY35090A (zh) |
WO (1) | WO2014064038A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020156312A1 (zh) * | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
WO2021083246A1 (zh) * | 2019-10-29 | 2021-05-06 | 上海翰森生物医药科技有限公司 | 四元环类衍生物调节剂、其制备方法和应用 |
WO2022228447A1 (zh) * | 2021-04-28 | 2022-11-03 | 上海翰森生物医药科技有限公司 | 含哌嗪多环类衍生物的盐及晶型及其制备方法和应用 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
AR095264A1 (es) | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
CN111801330B (zh) | 2018-01-26 | 2024-04-05 | 盐野义制药株式会社 | 具有多巴胺d3受体拮抗作用的稠环化合物 |
WO2019146740A1 (ja) | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンd3受容体拮抗作用を有する環式化合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008125891A2 (en) * | 2007-04-11 | 2008-10-23 | Richter Gedeon Nyrt | Pyrimidinyl-piperazines useful as dopamine d3 /d2 receptor ligands |
US20090143398A1 (en) * | 2007-12-03 | 2009-06-04 | Gizella Bartane Szalai | Pyrimidinyl-piperazines useful as d3/d2 receptor ligands |
CN101511805A (zh) * | 2006-06-22 | 2009-08-19 | 生物计划公司 | 作为多巴胺d3受体配体的新型羰基化(氮杂)环己烷类化合物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19728996A1 (de) | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
DE19735410A1 (de) | 1997-08-14 | 1999-02-18 | Basf Ag | 2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat |
DE10131543A1 (de) | 2001-06-29 | 2003-01-16 | Abbott Lab | Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung |
US20030166476A1 (en) | 2002-01-31 | 2003-09-04 | Winemiller Mark D. | Lubricating oil compositions with improved friction properties |
DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
TW200510395A (en) | 2003-06-05 | 2005-03-16 | Abbott Gmbh & Co Kg | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
DE102004027359A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
ATE452134T1 (de) | 2004-08-09 | 2010-01-15 | Abbott Gmbh & Co Kg | Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen |
DE102004061593A1 (de) | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
HUP0500170A3 (en) | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
BRPI0812840A2 (pt) | 2007-07-02 | 2014-12-09 | Hoffmann La Roche | 2-imidazolinas |
PA8802101A1 (es) | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
WO2010034648A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors |
US8586579B2 (en) | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
US8470828B2 (en) | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
-
2013
- 2013-10-11 US US14/051,626 patent/US9376396B2/en active Active
- 2013-10-21 KR KR1020157013554A patent/KR20150074154A/ko not_active Application Discontinuation
- 2013-10-21 WO PCT/EP2013/071947 patent/WO2014064038A1/en active Application Filing
- 2013-10-21 EP EP13785389.1A patent/EP2909201B1/en active Active
- 2013-10-21 SG SG11201503144VA patent/SG11201503144VA/en unknown
- 2013-10-21 UY UY0001035090A patent/UY35090A/es not_active Application Discontinuation
- 2013-10-21 CA CA2890247A patent/CA2890247A1/en not_active Abandoned
- 2013-10-21 JP JP2015537290A patent/JP2016500683A/ja active Pending
- 2013-10-21 NZ NZ630281A patent/NZ630281A/en not_active IP Right Cessation
- 2013-10-21 RU RU2015119241A patent/RU2015119241A/ru not_active Application Discontinuation
- 2013-10-21 CN CN201380067566.XA patent/CN104854103B/zh not_active Expired - Fee Related
- 2013-10-21 AU AU2013336787A patent/AU2013336787B2/en not_active Ceased
- 2013-10-21 BR BR112015008992A patent/BR112015008992A2/pt not_active IP Right Cessation
- 2013-10-21 MX MX2015005093A patent/MX2015005093A/es unknown
- 2013-10-22 TW TW102138129A patent/TWI607003B/zh not_active IP Right Cessation
- 2013-10-22 AR ARP130103832A patent/AR093099A1/es unknown
-
2015
- 2015-04-20 IL IL238392A patent/IL238392A/en not_active IP Right Cessation
- 2015-05-06 IN IN3837DEN2015 patent/IN2015DN03837A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101511805A (zh) * | 2006-06-22 | 2009-08-19 | 生物计划公司 | 作为多巴胺d3受体配体的新型羰基化(氮杂)环己烷类化合物 |
WO2008125891A2 (en) * | 2007-04-11 | 2008-10-23 | Richter Gedeon Nyrt | Pyrimidinyl-piperazines useful as dopamine d3 /d2 receptor ligands |
US20090143398A1 (en) * | 2007-12-03 | 2009-06-04 | Gizella Bartane Szalai | Pyrimidinyl-piperazines useful as d3/d2 receptor ligands |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020156312A1 (zh) * | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
CN111770754A (zh) * | 2019-01-30 | 2020-10-13 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
CN111770754B (zh) * | 2019-01-30 | 2023-09-19 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
WO2021083246A1 (zh) * | 2019-10-29 | 2021-05-06 | 上海翰森生物医药科技有限公司 | 四元环类衍生物调节剂、其制备方法和应用 |
CN113056454A (zh) * | 2019-10-29 | 2021-06-29 | 上海翰森生物医药科技有限公司 | 四元环类衍生物调节剂、其制备方法和应用 |
WO2022228447A1 (zh) * | 2021-04-28 | 2022-11-03 | 上海翰森生物医药科技有限公司 | 含哌嗪多环类衍生物的盐及晶型及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
SG11201503144VA (en) | 2015-06-29 |
KR20150074154A (ko) | 2015-07-01 |
US20140194437A1 (en) | 2014-07-10 |
IL238392A (en) | 2017-09-28 |
IN2015DN03837A (zh) | 2015-10-02 |
IL238392A0 (en) | 2015-06-30 |
EP2909201B1 (en) | 2017-02-22 |
AU2013336787B2 (en) | 2017-06-22 |
AR093099A1 (es) | 2015-05-20 |
AU2013336787A1 (en) | 2015-05-14 |
MX2015005093A (es) | 2015-09-25 |
TW201427957A (zh) | 2014-07-16 |
UY35090A (es) | 2014-05-30 |
BR112015008992A2 (pt) | 2017-07-04 |
NZ630281A (en) | 2016-08-26 |
WO2014064038A1 (en) | 2014-05-01 |
RU2015119241A (ru) | 2016-12-20 |
JP2016500683A (ja) | 2016-01-14 |
TWI607003B (zh) | 2017-12-01 |
EP2909201A1 (en) | 2015-08-26 |
US9376396B2 (en) | 2016-06-28 |
CA2890247A1 (en) | 2014-05-01 |
CN104854103B (zh) | 2018-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104854103A (zh) | 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 | |
EP2970146B1 (en) | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor | |
CN101611013B (zh) | 作为5-ht2a血清素受体调节剂用于治疗与其相关病症的吡唑衍生物 | |
CN103930407A (zh) | 用作激酶活性调节剂的氨基嘧啶衍生物 | |
CN103608343A (zh) | 用于制备作为大麻素受体调节剂的稠合氮杂环的晶形和制备方法 | |
CN101142180B (zh) | 作为组胺h3受体拮抗剂的吡咯烷衍生物 | |
US20040259882A1 (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
JP2008521859A (ja) | ドーパミンd3受容体の調節に応答する障害の治療に好適なトリアゾール化合物 | |
CN102124006B (zh) | (桥接的哌嗪基)-1-烷酮衍生物及其作为p75抑制剂的用途 | |
CN101932574B (zh) | 用于治疗对多巴胺d3受体调节产生反应的病症的1,2,4-三嗪-3,5-二酮化合物 | |
EP1484330B1 (en) | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
WO2022217232A1 (en) | Chromans and benzofurans as 5-ht1a and taar1 agonists | |
JP2009541251A (ja) | 置換フェニルメタノン誘導体 | |
JP5680416B2 (ja) | ドーパミンd3受容体の調節に応答する障害の治療に好適なベンゼンスルホンアミド化合物 | |
CN104995183A (zh) | 新的磷酸二酯酶10a型的抑制剂化合物 | |
US9388141B2 (en) | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | |
EP3442966B1 (en) | Novel n-[(pyrimidinylamino)propanyl]- and n-[(pyridinylamino)propanyl]arylcarboxamides | |
WO2024064178A1 (en) | Hexahydro-2h-pyrido[2,1-a]isoquinoline vmat2 inhibitors and methods of use | |
CN116323583A (zh) | 用于对亨廷顿蛋白成像的杂联芳基化合物和显像剂 | |
JP2020519694A (ja) | オレキシン受容体アンタゴニス | |
JP2004509881A (ja) | テトラヒドロフラン誘導体および治療薬としてのその使用 | |
CN104684912A (zh) | 磷酸二酯酶10a型的抑制剂化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: A. Houpute Inventor after: J. Dingley Inventor after: L. Unger Inventor after: K. Wicker Inventor after: RV Watersgut Inventor after: S. Mittelstedt Inventor after: K. Drexel Inventor after: A.rero Inventor before: A. Houpute |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160129 Address after: Wiesbaden Applicant after: Abbvie Germany GmbH & Co. KG Applicant after: AbbVie Corp. Address before: Wiesbaden Applicant before: Abbvie Germany GmbH & Co. KG |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180102 Termination date: 20181021 |